A high tide marker stands out on the beach, what stood out at ASGCT20 for you?
As Covid–19 continues to exert its impact on the cancer conference schedule, the good news is that it isn’t a total wrecking ball effect as organisations turn to virtual meetings to enable researchers to share their work.
Some of the events we have ‘attended’ this year have been prerecorded in advance, while others have taken the form of live events. Having listened to both, I can say they have advantages and disadvantages either way.
To me, it doesn’t really matter if you are flexible and appreciate the effort the scientists are making to show their wares.
This week it’s the turn of the American Society of Gene and Cell Therapy (ASGCT) to be in the spotlight with a truly ‘live’ meeting.
In the latest post, we focus on some key Gems from the Poster Halls…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASGCT meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
We often talk about ‘on-target off-target’ side effects, but what about the equivalent on-site off-the-reservation meetings? I’m a big fan of these, it has to be said.
Spring time in Chicago feels more like… October – brrrr!
My first day at AACR18 in Chicago this year was sandwiched by two such events, one of those welcome to AACR moments – never mind the frigid weather – to be sure.
First off, you have to be on the relevant distribution lists to get invited, then hope the organisers accept your registration, such is the life of scientists on the dark side (journalism/media).
In the past, these off-reservation scientific events around AACR have been well run and very useful for picking up new companies or targets ahead of the mainstream news and this year I wasn’t disappointed.
One of the Previews that I didn’t get time to write up was on CAR T cell therapies because there was a huge surfeit of new companies, new targets and lots of unproven mouse data, which is a recipe for speculation without representation (of clinical data). So on the basis that the good stuff will rise to the top, I figured that it might be more efficient to summarise an event instead, as past events have proven very useful in this somewhat singular approach.
We all know that we need to go beyond CD19 as a target in hematology malignancies, and that the promise in solid tumours is high, but data scant, so where are the gems to watch out for?
Here. we take a look at some up-and-coming approaches and companies to watch out for to cut to the chase for BSB readers interested in this space…
To learn more and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
The race to the be first to market in the United States with a CD19 directed CAR-T cell therapy is a bit like the America’s Cup Challenge Race Series – one boat/company is ahead and then another is ahead, it’s an ever changing and fluid situation…
In this post, we’re looking at questions from subscribers – so what’s in the July BSB mailbag?
* CAR T Cell Therapy: Is the recent FDA hold – that came and went in record time, a setback to Juno? Who will win the CAR-T race to market in the United States? What is the market opportunity in Europe?
* Jounce/Celgene Deal: Celgene have a reputation for doing deals with innovative biotech companies, but then what? Is the Jounce deal a good one, or is it a value destroyer?
There are a few other questions in the mail bag, but the above gives you a flavour of some of the commentary in this post.
Subscribers can login to read more or you can purchase access.